Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Promising new drugs and therapeutic approaches for treatment of ovarian cancer—targeting the hallmarks of cancer

Fig. 1

Sustaining proliferative signaling. Alterations in growth factors such as EGFR, FRα, ALK, AXL, and IGFR lead to constitutive activity in downstream signaling pathways. Most frequently affected are RAS/RAF/MAPK, PI3K/AKT/mTOR, and JAK/STAT pathway. Constitutive activity leads to dysregulated cell proliferation, cell survival, and cell cycle progression. Currently ongoing and recently completed phase III trials targeting those molecules are displayed in the table. This figure was created using Biorender.com [26, 29, 30, 34, 35, 38,39,40,41,42,43,44,45,46,47,48,49,50,51,52]

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us